These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19755281)

  • 21. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
    Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.
    Turco MA; Ormiston JA; Popma JJ; Mandinov L; O'Shaughnessy CD; Mann T; McGarry TF; Wu CJ; Chan C; Webster MW; Hall JJ; Mishkel GJ; Cannon LA; Baim DS; Koglin J
    J Am Coll Cardiol; 2007 Apr; 49(16):1676-83. PubMed ID: 17448368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of short- and mid-term outcomes between CYPHER and TAXUS stents in patients with complex lesions of the coronary arteries.
    Chen JL; Gao RL; Yang YJ; Qiao SB; Qin XW; Yao M; Liu HB; Xu B; Wu YJ; Yuan JQ; Chen J; Dai J; You SJ; Ma WH
    Chin Med J (Engl); 2006 Jan; 119(1):21-5. PubMed ID: 16454977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry.
    Buszman P; Trznadel S; Milewski K; Rzeźniczak J; Przewłocki T; Kośmider M; Wójcik J; Janczak J; Zurakowski A; Kondys M; Król M; Kinasz L; Jaklik A; Rzeszutko Ł; Kałuza GL; Kiesz S; Gil R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):51-7. PubMed ID: 18098182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions.
    Ormiston JA; Charles O; Mann T; Hall JJ; McGarry T; Cannon LA; Webster MW; Mishkel GJ; Underwood PL; Dawkins KD
    Coron Artery Dis; 2013 Jan; 24(1):61-8. PubMed ID: 23232250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry.
    Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):173-7. PubMed ID: 16144017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study.
    Ostojic M; Sagic D; Jung R; Zhang YL; Nedeljkovic M; Mangovski L; Stojkovic S; Debeljacki D; Colic M; Beleslin B; Milosavljevic B; Orlic D; Topic D; Karanovic N; Paunovic D; Christians U;
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):901-8. PubMed ID: 19016466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New stent design for use in small coronary arteries during percutaneous coronary intervention.
    Granada JF; Huibregtse BA; Dawkins KD
    Med Devices (Auckl); 2010; 3():57-66. PubMed ID: 22915922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results.
    Schurtz G; Delhaye C; Hurt C; Thieuleux H; Lemesle G
    Med Devices (Auckl); 2014; 7():35-43. PubMed ID: 24600254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late stent thrombosis after drug-eluting stent implantation: a rare case of accelerated neo-atherosclerosis and early manifestation of neointimal rupture.
    Yang YJ; Kim M; Kim C; Park J; Oh J; Won H; Kim BK; Hong MK
    Korean Circ J; 2011 Jul; 41(7):409-12. PubMed ID: 21860645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observation of early strut coverage after polymer-free biolimus-A9 coated stent by optical frequency domain imaging.
    Ochiumi Y; Suzuki Y
    J Cardiol Cases; 2019 May; 19(5):145-147. PubMed ID: 31073345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late Neointimal Regression 5 Years After Polymer-Free Biolimus A9-Coated Stent Implantation: A Case Report.
    Kusuda M; Ishihara T; Iida O; Tsujimura T; Hata Y; Toyoshima T; Higashino N; Nakao S; Mano T
    CJC Open; 2023 Nov; 5(11):802-804. PubMed ID: 38020337
    [No Abstract]   [Full Text] [Related]  

  • 37. Erratum for "Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent".
    Int Forum Allergy Rhinol; 2019 Aug; 9(8):945. PubMed ID: 31390492
    [No Abstract]   [Full Text] [Related]  

  • 38. A word of caution on unrestricted use of synthetic stent grafts in native coronary arteries.
    Haude M; Erbel R
    Catheter Cardiovasc Interv; 2000 Jun; 50(2):266-7. PubMed ID: 10842405
    [No Abstract]   [Full Text] [Related]  

  • 39. Correction to Supporting Information for Nobori et al., Transcriptome landscape of a bacterial pathogen under plant immunity.
    Proc Natl Acad Sci U S A; 2018 Dec; 115(49):E11564. PubMed ID: 30455299
    [No Abstract]   [Full Text] [Related]  

  • 40. Coronary stent infection.
    Hulshof PBJE; Selder J; Sigaloff KCE; Kamp O
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab441. PubMed ID: 34859187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.